OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization

Purpose: To identify baseline OCT predictors of the 3-year visual outcome for type 3 (T3) macular neovascularization (MNV) secondary to age-related macular degeneration (AMD) treated by anti-vascular endothelialParticipants: Forty eyes of 30 patients affected by exudative treatment-naive T3 MNV were enrolled.Methods: Baseline best-corrected visual acuity (BCVA) and several baseline OCT features were assessed and included in the analysis. Univariate and multivariate analyses served to identify risk factors associated with the 3-year BCVA.Main Outcome Measures: Baseline OCT features that are associated with bad or good visual outcomes of T3 MNV treated by anti-VEGF injections.Results: Mean baseline BCVA was 0.34 +/- 0.28 logarithm of the minimum angle of resolution (LogMAR), which significantly decreased to 0.52 +/- 0.37 LogMAR at the end of the 3-year follow-up (P = 0.002). In the univariate analysis, the following baseline features were associated with the 3-year BCVA outcome: baseline BCVA (P = 0.004), foveal involvement of exudation (P = 0.004), and presence of subretinal fluid (SRF; P = 0.004). In the multivariate model, baseline BCVA (P = 0.032), central macular thickness (P = 0.036), number of active T3 lesions (P = 0.034), and presence of SRF (P = 0.008) were associated with the 3-year BCVA outcome. Interestingly, 3-year BCVA was significantly lower in 19 eyes with SRF at the baseline (0.69 +/- 0.42 LogMAR) than 21 eyes without SRF (0.37 +/- 0.24 LogMAR; P = 0.004). Conclusion: We identified structural OCT features associated with BCVA outcome after 3-year treatment with anti-VEGF injections. In contrast to previous studies on neovascular AMD, in our series, the presence of SRF at baseline was the most significant independent negative predictor of functional outcomes. Current findings may be employed to identify less favorable T3 patterns potentially deserving a more intensive treatment. Ophthalmology Retina 2022;6:586-594 (c) 2022 by the American Academy of Ophthalmology